Title
First Time in Man Trial for Friulimicin B
A Double-Blind, Placebo-Controlled, Randomized, Dose-Escalating Study of Single (Part A) and Multiple (Part B) Intravenous Doses of Friulimicin B in Healthy Subjects
Phase
Phase 1Lead Sponsor
MerLion Pharmaceuticals GmbHStudy Type
InterventionalStatus
TerminatedIndication/Condition
Community Acquired Pneumonia Staphylococcal Skin InfectionsIntervention/Treatment
friulimicin b ...Study Participants
31The purpose of this study is to study the safety of single doses and multiple doses of Friulimicin B in healthy volunteers. The level of Friulimicin B will be measured in the subjects blood and urine. One part of the study will assess if Friulimicin B in the plasma of subjects has activity against bacteria.
Continued widespread use of antibiotics has promoted the spread of antibiotic resistance and has created an urgent need for antibacterial agents with no known cross resistance to other antibiotics available for humans. Friulimicin B has been shown to be highly active against a range of bacteria including such important pathogens such as methicillin resistant Staphylococcus aureus (MRSA), drug resistant Streptococcus pneumoniae and Glycopeptide resistant Enterococcus spp. These organisms are the causative agents in serious infections such as skin and soft tissue infections, pneumonia, bacteremia and endocarditis, complicated urinary tract infections, and osteomyelitis.
This study is the first use of Friulimicin B in man and will examine its safety and a preliminary study will assess if Friulimicin B in the plasma of subjects has activity against bacteria.
Intravenous, once daily, single dose
Inclusion Criteria: Male or female healthy subjects 18-55 years of age In good health Exclusion Criteria: Abnormal physical findings of clinical significance at the Screening examination or baseline which would interfere with the objectives of the study.
